Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment
— California, December 2021–May 2022 | MMWR Skip directly to site content Skip directly to …

Among US adults diagnosed with COVID-19, including those with previous infection or
vaccination, persons who were prescribed Paxlovid within 5 days of diagnosis had a 51 …

COVID-19 rebound after Paxlovid and Molnupiravir during January-June 2022 - PMC Back
to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …

Summary Background Nirmatrelvir plus ritonavir (Paxlovid) reduced the risk of
hospitalization or death by 89% in high-risk, ambulatory adults with COVID-19. We aimed at …

We read with interest the manuscript “Sensitivity and specificity of surveillance case
definitions in detection of influenza and respiratory syncytial virus among hospitalized …

Paxlovid associated with decreased hospitalization rate among adults with COVID-19 — United
States, April–September 2022 - PMC Back to Top Skip to main content NIH NLM Logo Access …

Covid-19: What is the evidence for the antiviral Paxlovid? | The BMJ Skip to main content
Intended for healthcare professionals Access provided by Google Indexer Subscribe My …

Background Paxlovid was granted an Emergency Use Authorization for the treatment of mild
to moderate coronavirus disease 2019 (COVID-19), based on the interim analysis of the …

We read with interest the article reported by JM Coulson et al. that three cases of COVID-19
rebound were associated with nirmatrelvir/ritonavir pre-hospital therapy. 1 Paxlovid …

This study aimed to examine the efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for
coronavirus disease 2019 (COVID‐19). PubMed, Cochrane Library, Web of Science …